CN109661231B - 用于非酒精性脂肪性肝炎和纤维化的治疗 - Google Patents
用于非酒精性脂肪性肝炎和纤维化的治疗 Download PDFInfo
- Publication number
- CN109661231B CN109661231B CN201780053972.9A CN201780053972A CN109661231B CN 109661231 B CN109661231 B CN 109661231B CN 201780053972 A CN201780053972 A CN 201780053972A CN 109661231 B CN109661231 B CN 109661231B
- Authority
- CN
- China
- Prior art keywords
- group
- use according
- substituted
- branched
- membered heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 47
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title claims abstract description 45
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title description 53
- 206010016654 Fibrosis Diseases 0.000 title description 19
- 230000004761 fibrosis Effects 0.000 title description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 61
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 239000002253 acid Substances 0.000 claims abstract description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 20
- 125000002837 carbocyclic group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 16
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 239000005864 Sulphur Substances 0.000 claims description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 abstract description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 14
- 239000000203 mixture Substances 0.000 description 12
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 229960005187 telmisartan Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 239000002585 base Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- LFULEKSKNZEWOE-UHFFFAOYSA-N propanil Chemical compound CCC(=O)NC1=CC=C(Cl)C(Cl)=C1 LFULEKSKNZEWOE-UHFFFAOYSA-N 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- -1 methoxy, ethoxy, propoxy, isopropoxy, butoxy Chemical group 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- CLHYKAZPWIRRRD-UHFFFAOYSA-N 1-hydroxypropane-1-sulfonic acid Chemical compound CCC(O)S(O)(=O)=O CLHYKAZPWIRRRD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- CUGDYSSBTWBKII-UHFFFAOYSA-N 6-(dimethylamino)hexane-1,2,3,4,5-pentol Chemical compound CN(C)CC(O)C(O)C(O)C(O)CO CUGDYSSBTWBKII-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101100293599 Caenorhabditis elegans nas-5 gene Proteins 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000012333 histopathological diagnosis Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
式(I)的化合物
Description
本发明涉及用于非酒精性脂肪性肝炎(NASH)和纤维化的新治疗。
非酒精性脂肪性肝炎(NASH)是一种肝脏疾病,特征在于肝脏中的: (1)脂肪变性(脂肪堆积),(2)小叶炎症,和(3)肝细胞破坏(气球样变)。其为非酒精性脂肪性肝病(NAFLD)组的一部分,所述非酒精性脂肪性肝病由良性肝脏脂肪变性开始,但可以发展为NASH、纤维化、具有永久性肝损伤的肝硬化、肝细胞癌和死亡。
NAFLD通常与肥胖症和2型糖尿病有关,其在全世界的发病率极高且持续升高。
在USA,据估计NASH出现在12%的成年群体和22%的糖尿病患者中。还估计15-25%的患有NASH的患者将发展为肝硬化(肝纤维化,即纤维组织在器官中的过量沉积)。NASH也相当大地增加了心血管意外事件的风险。
目前,对于治疗NASH不存在任何有效的药物,健康监管机构(FDA, EMA)认为NASH流行病的控制是优先考虑的事情。
因此,需要提供NASH的有效治疗。
本发明的一个目的是提供适用于预防和/或治疗NASH的化合物。
本发明的还一个目的是提供也可适用于预防和/或治疗纤维化,优选肝纤维化的化合物。
而且,通过阅读下述发明说明书将实现其它目的。
本发明涉及式(I)的化合物
其中
R1代表∶
-基团–C(O)CR4R5CR6R7C(O)OH;
-基团–C(OH)(H)CR4R5CR6R7C(O)OH;
-–(CH2)4C(O)OH基团;
m代表0至8的整数;
R2代表∶
-任选取代的C6至C10芳基基团;或
-任选取代的5至10-元杂芳基基团;
R3相同或不同,代表:
-直链或支链的、C1至C5优选地C1至C4烷基;例如,甲基、乙基、丙基、异丙基、丁基、叔丁基;任选地被碳环基团或杂环基团取代,所述碳环为5至10元、饱和的、部分不饱和的或芳香族的、取代的或非取代的碳环,所述杂环包括5至10元、取代的或非取代的、饱和的、部分不饱和的或芳香族的杂环且其可以包括1、2或3个杂原子,所述杂原子相同或不同,特别地选自氮、氧或硫,
R4、R5、R6和R7相同或不同,代表:
-氢原子;
-直链或支链的、C1至C5优选地C1至C4的烷基;
-5、6或7-元饱和的、部分不饱和的或芳香族的、非取代的或取代的碳环基团;或
R4和R5与它们键合的碳原子一起形成具有5、6或7元、取代的或非取代的、优选饱和的碳环;例如环戊基或环己基;或
R6和R7与它们键合的碳原子一起形成具有5、6或7元、取代的或非取代的、优选饱和的碳环;例如环戊基或环己基;
或其对映异构体、其非对映异构体及其与可药用碱或酸的加成盐,
用于预防或治疗,优选地治疗NASH。
在本发明中,“用于治疗Y的化合物X”等同于“在治疗Y的方法中使用的化合物X”或“在治疗Y中使用的化合物X”。
术语杂芳基指包括至少一个相同或不同的选自O、N、S,优选N 的杂原子的5至10元杂芳基。杂芳基可以包括1、2、3或4个相同或不同的选自O、N、S,优选N的杂原子,优选地1、2或3个相同或不同的杂原子。
所述碳环、杂环、芳基、杂芳基为非取代的或被一个或多个相同或不同的取代基取代,所述取代基特别地选自:
-直链或支链的C1至C6烷氧基,例如甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基或叔丁氧基;
-卤素原子;
-直链或支链的烃基,优选地C1至C5优选地C1至C4烷基,例如,甲基、乙基、丙基、丁基、异丙基、叔丁基;
-直链或支链的烃基,优选地C1至C5优选地C1至C4烷基,特别地被一个或多个卤素原子取代;
-氰基(-CN)基团;或
-磺酰基烷基(-S(O)2-烷基)基团,其中所述烷基为直链或支链的、 C1至C5优选地C1至C4烷基,例如甲基、乙基、丙基、丁基、异丙基或叔丁基;
-具有5、6或7元、饱和的、部分不饱和的或芳香族优选苯基的、取代的或非取代的碳环基团,特别地被一个或多个相同或不同的选自下述的取代基取代:卤素原子,直链或支链的C1至C6烷氧基,例如甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基或叔丁氧基;C1至C5烷基,优选地C1至C4烷基,例如甲基、乙基、丙基、丁基、异丙基或叔丁基。
优选地,在本发明的化合物中,m为0。
优选地,在本发明的化合物中,R1为–C(O)CH2CH2C(O)OH或–(CH2)4C(O)OH。
优选地,在本发明的化合物中,R1为–C(O)CH2CH2C(O)OH。
优选地,在本发明的化合物中,R2代表∶
-C6至C10芳基基团,任选地被至少一个选自下述的取代基取代:直链或支链的C1-C6烷基,或直链或支链的O-(C1-C6)-烷基,优选地直链或支链的O-(C1-C3)-烷基;或
-5至10-元杂芳基基团。
优选地,在本发明的化合物中,R2代表:
-5至10-元杂芳基基团。
优选地,在本发明的化合物中,R1为–C(O)CH2CH2C(O)OH和m为0。
优选地,在本发明的化合物中,
m为0;和
R2代表∶
-C6至C10芳基基团,任选地被至少一个选自下述的取代基取代:直链或支链的C1-C6烷基,或直链或支链的O-(C1-C6)-烷基,优选地直链或支链的O-(C1-C3)-烷基;或
-5至10-元杂芳基基团。
优选地,在本发明的化合物中,
m为0;和
R2代表∶
-5至10-元杂芳基基团。
优选地,在本发明的化合物中,
R1为–C(O)CH2CH2C(O)OH,和
R2代表∶
-C6至C10芳基基团,任选地被至少一个选自下述的取代基取代:直链或支链的C1-C6烷基,或直链或支链的O-(C1-C6)-烷基,优选地直链或支链的O-(C1-C3)-烷基;或
-5至10-元杂芳基基团。
优选地,在本发明的化合物中,
R1为–C(O)CH2CH2C(O)OH,和
R2代表:
-5至10-元杂芳基基团。
优选地,在本发明的化合物中,
R1为–C(O)CH2CH2C(O)OH
m为0,和
R2代表:
-C6至C10芳基基团,任选地被至少一个选自下述的取代基取代:直链或支链的C1-C6烷基,或直链或支链的O-(C1-C6)-烷基,优选地直链或支链的O-(C1-C3)-烷基;或
-5至10-元杂芳基基团。
优选地,在本发明的化合物中,
R1为–C(O)CH2CH2C(O)OH
m为0,和
-5至10-元杂芳基基团。
优选地,在本发明的化合物中,R2代表∶
-苯基基团,任选地被至少一个选自下述的取代基取代:直链或支链的C1-C6烷基,或直链或支链的O-(C1-C6)-烷基,优选地直链或支链的O-(C1-C3)-烷基;或
-6-元杂芳基基团,优选地包括至少一个氮,优选吡啶。
优选地,在本发明的化合物中,R2代表:
-6-元杂芳基基团,优选地包括至少一个氮,优选吡啶。
优选地,在本发明的化合物中,
m为0;和
R2代表:
-苯基基团,任选地被至少一个选自下述的取代基取代:直链或支链的C1-C6烷基,或直链或支链的O-(C1-C6)-烷基,优选地直链或支链的O-(C1-C3)-烷基;或
-6-元杂芳基基团,优选地包括至少一个氮,优选吡啶。
优选地,在本发明的化合物中,
m为0;和
R2代表:
-6-元杂芳基基团,优选地包括至少一个氮,优选吡啶。
优选地,在本发明的化合物中,
R1为–C(O)CH2CH2C(O)OH;和
R2代表:
-苯基基团,任选地被至少一个选自下述的取代基取代:直链或支链的C1-C6烷基,或直链或支链的O-(C1-C6)-烷基,优选地直链或支链的O-(C1-C3)-烷基;或
-6-元杂芳基基团,优选地包括至少一个氮,优选吡啶。
优选地,在本发明的化合物中,
R1为–C(O)CH2CH2C(O)OH;和
R2代表∶
-6-元杂芳基基团,优选地包括至少一个氮,优选吡啶。
优选地,在本发明的化合物中,
R1为–C(O)CH2CH2C(O)OH;
m为0,和
R2代表∶
-苯基基团,任选地被至少一个选自下述的取代基取代:直链或支链的C1-C6烷基,或直链或支链的O-(C1-C6)-烷基,优选地直链或支链的O-(C1-C3)-烷基;或
-6-元杂芳基基团,优选地包括至少一个氮,优选吡啶。
优选地,在本发明的化合物中,
R1为–C(O)CH2CH2C(O)OH;
m为0,和
R2代表∶
-6-元杂芳基基团,优选地包括至少一个氮,优选吡啶。
根据本发明的化合物可以如在WO2012/17515和 WO2012/175707(将其通过援引并入本文中)中提及的合成。
式(I)的化合物具有羧基官能团,且可以成盐。然后,它们可以是与有机碱或无机碱的加成盐形式。与碱的加成盐为例如可药用盐,比如钠盐、钾盐或钙盐,其是使用相应的碱金属和碱土金属氢氧化物作为碱获得的。作为与可药用碱的加成盐的另外的形式,可以提及与胺且特别是葡糖胺、N-甲基葡糖胺、N,N-二甲基葡糖胺、乙醇胺、吗啉、 N-甲基吗啉或赖氨酸的盐。
式(I)的化合物也可以与无机酸或有机酸成盐,且优选地与药用酸成盐,所述药用酸比如盐酸、磷酸、富马酸、柠檬酸、草酸、硫酸、抗坏血酸、酒石酸(tartric acid)、马来酸、扁桃酸、甲烷基磺酸、乳糖酸、葡糖酸、葡糖二酸、琥珀酸、磺酸或羟基丙烷磺酸。
本发明的化合物用于治疗或预防优选地治疗NASH。
本发明还涉及药物组合物,包括作为有效成分的至少一种根据本发明的化合物,用于预防或治疗,优选地治疗NASH。这些组合物也可包括可药用媒介物和/或赋形剂。
药物组合物可以是本领域技术人员已知的任何形式,特别是预期用于肠胃外、口服、直肠、经粘膜(permucosal)或经皮方法优选地口服给药的形式。
根据本发明的组合物将以下述形式存在:可注射的溶质或悬浮液或多剂量烧瓶的形式,素片(bare tablets)或包衣片、丸剂、胶囊、粉剂、栓剂或直肠胶囊、溶液或悬浮液的形式,用于经皮用途(在极性溶剂中),或经粘膜(permucosal)用途。
对于固体形式,适用于这种给药的赋形剂为纤维素或微晶纤维素的衍生物、碱土碳酸盐、磷酸镁、淀粉、改性淀粉或乳糖。
对于直肠使用,可可脂或硬脂酸聚乙二醇酯是优选的赋形剂。
对于肠胃外使用,水、水性溶质、生理学血清和等渗溶质是最方便使用的媒介物。
剂量学可以根据治疗适应症和给药方法、以及受试者的年龄和体重在很大限度之内变化。
本发明还涉及一种预防或治疗,优选地治疗NASH的方法,包括向如此需要的患者给药足够量的至少一种根据本发明的化合物与可药用媒介物或赋形剂。
如上所述需要治疗的患者的鉴别由本领域技术人员定义。兽医或医生可以利用临床试验、身体检查、生物检验或诊断和通过家庭和/ 或病史鉴别需要这种治疗的受试者。
足够量指有效地预防或治疗病理学病症的根据本发明的化合物的量。足够量可以由本领域技术人员利用常规技术和通过观察在类似情形中得到的结果确定。为了确定足够量,本领域技术人员必须考虑各种因素,特别地且不限于此:受试者、其尺码、其年龄、其整体健康状况、涉及的疾病及其严重程度;受试者的反应、化合物的类型、给药方法、给药组合物的生物利用度、剂量、同时使用的其它药物等。优选地,以一个或多个剂量,优选地以一个剂量向患者给药5至500 mg/天的根据本发明的化合物。
本发明还涉及一种预防或治疗,优选地治疗NASH的方法,包括向需要其的患者给药足量的至少一种根据本发明的组合物。
本发明还涉及式(I)的化合物在制备用于预防或治疗,优选地治疗 NASH的药物中的用途。
本发明还涉及根据本发明的组合物在制备用于预防或治疗,优选地治疗NASH的药物中的用途。
除了治疗NASH之外,根据本发明的化合物还用于治疗纤维化,优选肝纤维化。实际上,本发明还涉及用于预防或治疗,优选地治疗纤维化优选肝纤维化的根据本发明的化合物。本发明还涉及用于预防或治疗,优选地治疗纤维化优选肝纤维化的根据本发明的组合物。
本发明还涉及一种预防或治疗,优选地治疗纤维化优选肝纤维化的方法,包括向如此需要的患者给药足量的至少一种根据本发明的化合物或组合物与可药用媒介物或赋形剂。
本发明还涉及根据本发明的化合物或组合物在制备用于预防或治疗,优选地治疗纤维化优选肝纤维化的药物中的用途。
本发明还涉及用于预防或治疗,优选地治疗NASH和纤维化优选肝纤维化的根据本发明的化合物。本发明还涉及用于预防或治疗,优选地治疗NASH和纤维化优选肝纤维化的根据本发明的组合物。
本发明还涉及一种预防或治疗,优选地治疗NASH和纤维化优选肝纤维化的方法,包括向如此需要的患者给药足量的至少一种根据本发明的化合物或组合物与可药用媒介物或赋形剂。
本发明还涉及根据本发明的化合物或组合物在制备用于预防或治疗,优选地治疗NASH和纤维化优选肝纤维化的药物中的用途。
现在,本发明将借助于非限制性实施例进行描述。
已经测试了下述式(I)的化合物(1)∶
如WO 2012/175715中描述的获得该化合物。
该研究在STAM模型上进行。
从日本SLC,Inc.(日本)获得无病原体的十四天妊娠C57BL/6小鼠。通过产后单次皮下注射链脲佐菌素(Sigma,USA)和在四周龄(28 ±2天)之后不限量饲喂高脂肪饮食(CLEA日本,日本)在雄性小鼠中建立NASH。在开始治疗之前的数天中,将六周龄(42±2天)的小鼠随机分成三组,每组10只,并且将九周龄(63±2天)的小鼠分成三组,每组10只。在治疗期间,每日测量个体体重。在治疗期间,每周两次测量食物消耗。每日监测小鼠的存活、临床征兆和行为。
评价对于NASH作用的体内研究1
NASH体内研究具有3组(arms):
第1组(媒介物)∶向10只NASH小鼠口服给药与接受化合物(1) 的小鼠相同的媒介物(0.5%甲基纤维素水溶液)。
第2组(替米沙坦)∶从第六至第九(6至9)周龄,每日一次向五只小鼠给药补充有100mg/kg剂量的替米沙坦的相同媒介物(0.5%甲基纤维素水溶液)。替米沙坦,一种血管紧张素受体阻断剂,是参考化合物,其已被证明在STAM动物模型中治疗NASH和纤维化是有活性的。
第3组(化合物(1))∶从第六至第九(6至9)周龄,每日一次向十只NASH小鼠口服给药补充有100mg/kg剂量的化合物(1)的相同媒介物(0.5%甲基纤维素水溶液)。评价的参数和组织学结果测量方法描述如下。
评价对于纤维化作用的体内研究2
纤维化体内研究具有3组:
第1组(媒介物)∶向10只NASH小鼠口服给药与接受化合物(1) 的小鼠相同的媒介物(0.5%甲基纤维素水溶液)。
第2组(替米沙坦)∶从第九至第十二(9至12)周龄,每日一次向五只小鼠给药补充有100mg/kg剂量的替米沙坦的相同媒介物(0.5%甲基纤维素水溶液)。
第3组(化合物(1))∶从第九至第十二(9至12)周龄,每日一次向十只NASH小鼠口服给药补充有100mg/kg剂量的化合物(1)的相同媒介物(0.5%甲基纤维素水溶液)。评价的参数和组织学结果测量方法描述如下。
研究测量方法、分析物、结果和分析
对于两个体内研究,进行下述测量:
·个体肝重
·个体体重
·通过FUJI DRI-CHEM(Fujifilm,日本)测量血浆ALT(丙氨酸氨基转移酶),AST(天门冬氨酸氨基转移酶),甘油三酯和总胆固醇。
·通过甘油三酯E-试验试剂盒(Wako,日本)定量肝甘油三酯。
·组织学分析肝部分(根据常规方法)
·HE(苏木精伊红)染色和NAFLD活性评分(NAS)的评估
NAS的定义和计算
NASH临床研究网络(Clinical Research Network)提议的NAFLD 活性评分(NAS)是NAFLD/NASH研究领域中最广泛使用的评分系统 (Kleiner,DE.,等人,(2005).Designand validation of a histological scoring system for nonalcoholic fatty liverdisease.Hepatology,41,1313-21)。
NAS定义为对于代表活化肝损伤(active liver injury)的脂肪变性(0-3)、小叶炎症(0-3)和肝细胞气球样变(0-2)的组织学评分的未加权总和(见表)。在临床和非临床试验中,NAS得到0至8的总分,并且能够详细分析比较研究和相关研究的组织学变化。
NAS最初被研究用于评价而非诊断NAFLD/NASH。然而,所述评分通常被用于NASH诊断,NAS 5被认为是阈值。尽管NAS显示出与诊断的良好相关性,但是必须需要仔细的解释。存在的情形是,其中非NASH 肝可评分为总NAS≥5,或者相反地,具有NAS≤4的肝可得到NASH的诊断(Brunt,EM.,等人,(2011)。Nonalcoholic fatty liver disease (NAFLD)activity score and the histopathologic diagnosis in NAFLD:distinctclinicopathologic meanings.Hepatology,53, 810-20and Hjelkrem,M.,等人,(2011).Validation of the non-alcoholic fatty liver disease activity score.Aliment.Pharmacol.Ther.,34,214-8)。
在评价药物功效的情况下,当严格地应用于组织学证实的NASH 患者时,NAS是有用的。从非临床研究的方面来看,当应用于NASH病理学的不稳定发病(uneven onset)的动物模型时,应当小心地使用 NAS。
由于Stelic的专有NASH-HCC模型(STAM模型)具有均一且可再现的[100%]疾病进程,STAM模型对于使用NAS进行比较研究是有利的。
·2002年由国家糖尿病消化与肾病研究所(National Institute of Diabetesand Digestive and Kidney Diseases)(NIDDK)建立了研究成人和儿童脂肪性肝病的自然病史(natural history) 和进行临床试验的网络。
NAS构成的定义
表1NAFLD活性评分的构成(Kleiner等人,2005)
结果以附图给出。
图1表示研究1和2中各个组1(媒介物)、2(替米沙坦)和3(根据本发明的化合物)的NAS评分。
图2显示研究1和2中各个组1(媒介物)、2(替米沙坦)和3(根据本发明的化合物)的肝中甘油三酯的量。
图3显示研究1和2中各个组1(媒介物)、2(替米沙坦)和3(根据本发明的化合物)的血浆中甘油三酯的量。
与媒介物和替米沙坦相比,在研究1和2中,根据本发明的化合物(1)显示NAFLD活性评分(NAS)显著降低。
根据本发明的化合物(1)显示肝甘油三酯(TG)的量减少。
根据本发明的化合物(1)显示血浆甘油三酯(TG)的量减少,特别是在研究2中。
Claims (18)
1.式(I)的化合物在制备用于预防或治疗NASH的药物中的用途:
其中
R1代表:
-基团–C(O)CR4R5CR6R7C(O)OH;
或
-–(CH2)4C(O)OH基团;
m代表0至8的整数;
R2代表:
-任选取代的C6至C10芳基基团;或
-任选取代的5至10-元杂芳基基团;
R3相同或不同,代表:
-直链或支链的C1至C5烷基;任选地被碳环基团或杂环基团取代,所述碳环为5至10元、饱和的、部分不饱和的或芳香族的、取代的或非取代的碳环,所述杂环包括5至10元、取代的或非取代的、饱和的、部分不饱和的或芳香族的杂环且其可以包括1、2或3个杂原子,所述杂原子相同或不同,选自氮、氧或硫,
R4、R5、R6和R7相同或不同,代表:
-氢原子;
-直链或支链的C1至C5烷基;
-5、6或7-元饱和的、部分不饱和的或芳香族的、非取代的或取代的碳环基团;或
R4和R5与它们键合的碳原子一起形成具有5、6或7元、取代的或非取代的的碳环;或
R6和R7与它们键合的碳原子一起形成具有5、6或7元、取代的或非取代的的碳环;
或其对映异构体、其非对映异构体及其与可药用碱或酸的加成盐。
2.根据权利要求1的用途,其中m为0。
3.根据权利要求1或2的用途,其中R1为–C(O)CH2CH2C(O)OH或–(CH2)4C(O)OH。
4.根据权利要求1或2的用途,其中R1为–C(O)CH2CH2C(O)OH。
5.根据权利要求1或2的用途,其中R2代表∶
-C6至C10芳基基团,任选地被至少一个选自下述的取代基取代:直链或支链的C1-C6烷基,或直链或支链的O-(C1-C6)-烷基;或
-5至10-元杂芳基基团。
6.根据权利要求5的用途,其中R2代表5至10-元杂芳基基团。
7.根据权利要求6的用途,其中R2代表6-元杂芳基基团。
8.根据权利要求7的用途,其中R2代表吡啶。
9.根据权利要求1或2的用途,其中R3代表甲基、乙基、丙基、异丙基、丁基、叔丁基;
R4和R5与它们键合的碳原子一起形成环戊基或环己基;或
R6和R7与它们键合的碳原子一起形成环戊基或环己基。
10.式(I)的化合物在制备用于预防或治疗肝纤维化的药物中的用途:
其中
R1代表:
-基团–C(O)CR4R5CR6R7C(O)OH;
或
-–(CH2)4C(O)OH基团;
m代表0至8的整数;
R2代表:
-任选取代的C6至C10芳基基团;或
-任选取代的5至10-元杂芳基基团;
R3相同或不同,代表:
-直链或支链的、C1至C5烷基;任选地被碳环基团或杂环基团取代,所述碳环为5至10元、饱和的、部分不饱和的或芳香族的、取代的或非取代的碳环,所述杂环包括5至10元、取代的或非取代的、饱和的、部分不饱和的或芳香族的杂环且其可以包括1、2或3个杂原子,所述杂原子相同或不同,选自氮、氧或硫,
R4、R5、R6和R7相同或不同,代表:
-氢原子;
-直链或支链的、C1至C5烷基;
-5、6或7-元饱和的、部分不饱和的或芳香族的、非取代的或取代的碳环基团;或
R4和R5与它们键合的碳原子一起形成具有5、6或7元、取代的或非取代的的碳环;或
R6和R7与它们键合的碳原子一起形成具有5、6或7元、取代的或非取代的的碳环;或其对映异构体、其非对映异构体及其与可药用碱或酸的加成盐。
11.根据权利要求10的用途,其中m为0。
12.根据权利要求10或11的用途,其中R1为–C(O)CH2CH2C(O)OH或–(CH2)4C(O)OH。
13.根据权利要求10或11的用途,其中R1为–C(O)CH2CH2C(O)OH。
14.根据权利要求10或11的用途,其中R2代表∶
-C6至C10芳基基团,任选地被至少一个选自下述的取代基取代:直链或支链的C1-C6烷基,或直链或支链的O-(C1-C6)-烷基;或
-5至10-元杂芳基基团。
15.根据权利要求14的用途,其中R2代表5至10-元杂芳基基团。
16.根据权利要求15的用途,其中R2代表6-元杂芳基基团。
17.根据权利要求16的用途,其中R2代表吡啶。
18.根据权利要求10或11的用途,其中R3代表甲基、乙基、丙基、异丙基、丁基、叔丁基;
R4和R5与它们键合的碳原子一起形成环戊基或环己基;或
R6和R7与它们键合的碳原子一起形成环戊基或环己基。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16306010.6A EP3278802A1 (en) | 2016-08-04 | 2016-08-04 | New treatment for the non alcoholic steatohepatitis and fibrosis |
EP16306010.6 | 2016-08-04 | ||
PCT/EP2017/069595 WO2018024805A1 (en) | 2016-08-04 | 2017-08-03 | New treatment for the non alcoholic steatohepatitis and fibrosis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109661231A CN109661231A (zh) | 2019-04-19 |
CN109661231B true CN109661231B (zh) | 2021-08-24 |
Family
ID=56683865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780053972.9A Active CN109661231B (zh) | 2016-08-04 | 2017-08-03 | 用于非酒精性脂肪性肝炎和纤维化的治疗 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11324743B2 (zh) |
EP (2) | EP3278802A1 (zh) |
JP (1) | JP2019523288A (zh) |
KR (1) | KR20190034642A (zh) |
CN (1) | CN109661231B (zh) |
AU (1) | AU2017307341A1 (zh) |
BR (1) | BR112019002151A2 (zh) |
CA (1) | CA3032607A1 (zh) |
RU (1) | RU2762280C2 (zh) |
WO (1) | WO2018024805A1 (zh) |
ZA (1) | ZA201900707B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102177304B1 (ko) * | 2018-07-23 | 2020-11-10 | 제이투에이치바이오텍 (주) | 비알콜성 지방간염의 예방 또는 치료용 약학 조성물 |
CN114555076B (zh) * | 2019-10-18 | 2024-02-02 | 正大天晴药业集团股份有限公司 | 用于治疗非酒精性脂肪性肝炎的药物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002100341A2 (en) * | 2001-06-12 | 2002-12-19 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
WO2012175715A1 (fr) * | 2011-06-23 | 2012-12-27 | Metabolys | Dérivés de pipérazine, leurs procédés de préparation et leurs utilisations dans le traitement de l'insulinorésistance |
WO2012175707A1 (fr) * | 2011-06-23 | 2012-12-27 | Metabolys | Dérivés de pipérazine, leurs procédés de préparation et leurs utilisations dans le traitement de l'insulinorésistance |
WO2014095929A1 (fr) * | 2012-12-17 | 2014-06-26 | Metabolys | Composition et kit comprenant des dérivés de pipérazine et de la metformine, leur utilisation dans le traitement du diabète |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2902426B1 (fr) | 2006-06-19 | 2008-09-05 | Pierre Fabre Medicament Sa | Derives de cinnamoyl-piperazine |
US20080194575A1 (en) * | 2006-10-04 | 2008-08-14 | Naiara Beraza | Treatment for non-alcoholic-steatohepatitis |
WO2009151116A1 (ja) * | 2008-06-13 | 2009-12-17 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防/改善・治療薬 |
CA2798735A1 (en) | 2010-05-19 | 2011-11-24 | Haruki Shibata | Prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis |
WO2012017515A1 (ja) | 2010-08-03 | 2012-02-09 | ミライアル株式会社 | マイクロ流路デバイス |
-
2016
- 2016-08-04 EP EP16306010.6A patent/EP3278802A1/en not_active Withdrawn
-
2017
- 2017-08-03 CN CN201780053972.9A patent/CN109661231B/zh active Active
- 2017-08-03 KR KR1020197006323A patent/KR20190034642A/ko not_active Application Discontinuation
- 2017-08-03 BR BR112019002151A patent/BR112019002151A2/pt not_active Application Discontinuation
- 2017-08-03 WO PCT/EP2017/069595 patent/WO2018024805A1/en unknown
- 2017-08-03 EP EP17751695.2A patent/EP3493806A1/en active Pending
- 2017-08-03 AU AU2017307341A patent/AU2017307341A1/en not_active Abandoned
- 2017-08-03 JP JP2019505430A patent/JP2019523288A/ja active Pending
- 2017-08-03 RU RU2019105810A patent/RU2762280C2/ru active
- 2017-08-03 CA CA3032607A patent/CA3032607A1/en not_active Abandoned
- 2017-08-03 US US16/323,094 patent/US11324743B2/en active Active
-
2019
- 2019-02-04 ZA ZA2019/00707A patent/ZA201900707B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002100341A2 (en) * | 2001-06-12 | 2002-12-19 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
WO2012175715A1 (fr) * | 2011-06-23 | 2012-12-27 | Metabolys | Dérivés de pipérazine, leurs procédés de préparation et leurs utilisations dans le traitement de l'insulinorésistance |
WO2012175707A1 (fr) * | 2011-06-23 | 2012-12-27 | Metabolys | Dérivés de pipérazine, leurs procédés de préparation et leurs utilisations dans le traitement de l'insulinorésistance |
WO2014095929A1 (fr) * | 2012-12-17 | 2014-06-26 | Metabolys | Composition et kit comprenant des dérivés de pipérazine et de la metformine, leur utilisation dans le traitement du diabète |
Also Published As
Publication number | Publication date |
---|---|
WO2018024805A1 (en) | 2018-02-08 |
US11324743B2 (en) | 2022-05-10 |
AU2017307341A1 (en) | 2019-02-21 |
KR20190034642A (ko) | 2019-04-02 |
CA3032607A1 (en) | 2018-02-08 |
EP3493806A1 (en) | 2019-06-12 |
RU2762280C2 (ru) | 2021-12-17 |
US20190160057A1 (en) | 2019-05-30 |
JP2019523288A (ja) | 2019-08-22 |
RU2019105810A (ru) | 2020-09-04 |
ZA201900707B (en) | 2022-04-28 |
EP3278802A1 (en) | 2018-02-07 |
RU2019105810A3 (zh) | 2020-09-04 |
CN109661231A (zh) | 2019-04-19 |
BR112019002151A2 (pt) | 2019-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hayashizaki-Someya et al. | Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats | |
US20130072459A1 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
US10959963B2 (en) | Method for the treatment of fatty liver disease | |
SG190850A1 (en) | Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers, and liver health maintenance | |
RU2765101C1 (ru) | Фармацевтическая композиция для предотвращения или лечения неалкогольного стеатогепатита | |
KR20170095302A (ko) | 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물 | |
KR101516677B1 (ko) | 지방성 간 질환의 치료용 의약 조성물 | |
WO2012104402A1 (en) | Treatment of severe persitent asthma with masitinib | |
CN109661231B (zh) | 用于非酒精性脂肪性肝炎和纤维化的治疗 | |
US20190231770A1 (en) | Combination compositions comprising fxr agonists for treating or preventing a fibrotic, cirrhotic disease or disorder | |
WO2020191501A1 (en) | Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders | |
AU2018376904B2 (en) | FXR agonists for the treatment of liver diseases | |
CN111225666A (zh) | 用于治疗、预防或改善肝纤维化的γ-酮醛清除剂的组合物和使用方法 | |
KR20150036115A (ko) | 위식도 역류증에 대한 약제 | |
EA043008B1 (ru) | Комбинации эдаравона для лечения ишемических повреждений мозга |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |